Equities

Veritas Farms Inc

VFRM:QBB

Veritas Farms Inc

Actions
  • Price (USD)0.013
  • Today's Change-0.005 / -27.78%
  • Shares traded6.25k
  • 1 Year change-73.47%
  • Beta1.2022
Data delayed at least 15 minutes, as of May 16 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Veritas Farms, Inc. (Veritas Farms) is an agribusiness that is focused on growing, producing, marketing, and distributing quality, whole plant, full spectrum hemp oils and extracts containing naturally occurring phytocannabinoids (collectively, CBD). Veritas Farms owns and operates an approximately 140 acres farm in Pueblo, Colorado, capable of producing over 200,000 proprietary full spectrum hemp plants, which can potentially yield a minimum annual harvest of 250,000 to 300,000 pounds of outdoor-grown industrial hemp. Veritas Farm's products include capsules, gummies, tinctures, lotions, salves, creams, balm sticks, lip balms, and pet chews. It also operates approximately 15,000 square feet of climate-controlled greenhouses to produce a consistent supply of year-round indoor-cultivated hemp. In addition, there is a 10,000 square-foot onsite facility used for processing raw hemp, oil extraction, formulation laboratories, and quality/purity testing.

  • Revenue in USD (TTM)730.65k
  • Net income in USD-6.15m
  • Incorporated2011
  • Employees17.00
  • Location
    Veritas Farms Inc1815 GRIFFIN ROAD, SUITE 401DANIA BEACH 33004United StatesUSA
  • Phone+1 (954) 722-1300
  • Websitehttps://theveritasfarms.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
VFRM:QBB since
announced
Transaction
value
ASYSTEM IncDeal completed28 Aug 202328 Aug 2023Deal completed-35.00%--
Brunsdon Employee Benefits LtdDeal completed03 Aug 202303 Aug 2023Deal completed-35.00%--
Inser SpAAnnounced11 Jul 202311 Jul 2023Announced-67.50%--
Data delayed at least 15 minutes, as of May 16 2024.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
cbdMD Inc21.58m-25.65m2.77m52.00--0.707--0.1283-19.96-19.969.271.010.89492.0921.27415,039.60-89.78-38.59-118.26-41.5062.7063.80-100.33-87.980.6107-3.010.4668---31.77120.9163.64---4.95--
Panacea Life Sciences Holdings Inc2.76m-7.67m2.81m40.00------1.02-0.4554-0.45540.164-0.52550.15371.6210.1369,098.25-42.65-69.04---225.03-139.49-181.62-277.51-505.410.0285-2.124.79--46.59--12.33------
Novelstem International Corp12.00k-4.19m2.81m15.00------234.41-0.0893-0.08930.0003-0.04160.0053--2.00---171.11---188.15-------32,373.50-----9.822.20--0.00---446.84------
Eloxx Pharmaceuticals Inc0.00-20.48m2.83m18.00---------9.06-9.060.00-6.530.00----0.00-124.43-115.27---155.33-----------16.69--------45.95---22.56--
Resonate Blends Inc16.47k-1.42m2.84m6.00------172.21-0.0178-0.01780.0002-0.02470.0237-------203.52-680.29-----593.02-78.88-8,597.33-12,895.26---0.46917.89---66.73-56.57-316.63------
Avenue Therapeutics Inc0.00-7.18m2.87m3.00--0.7762-----39.36-39.360.004.810.00----0.00-123.08-186.91-1,045.52-287.70------------0.00-------192.15------
Mosaic Immunoengineering Inc0.00-1.01m2.90m3.00---------0.1397-0.13970.00-0.81070.00----0.00-457.45-----------------35.84--------57.65------
Regen BioPharma Inc236.58k-851.69k2.90m1.00------12.26-0.2271-0.22710.0633-1.260.8644--3.98236,580.00-327.54-104.36---------378.93-275.00---1.32----0.441618.79-58.11------
Axim Biotechnologies Inc39.77k-8.06m2.91m6.00------73.29-0.0366-0.03660.0001-0.03110.0095----6,628.33-193.43-154.34---390.73-----20,265.75-36,362.71---0.62----345.05-27.38-29.10------
Veritas Farms Inc730.65k-6.15m2.95m17.00--14.57--4.04-0.1319-0.13190.01360.00130.08770.80647.8042,979.41-69.02-72.11-123.21-93.59-220.0924.07-787.27-177.790.1392-5.560.95---63.42-0.942723.68---52.93--
Livewire Ergogenics Inc67.98k-1.09m2.98m1.00------43.78-0.0061-0.00610.0003-0.00220.19791.742.8667,980.00-317.45-------113.70---1,604.38--0.1248-2.13----68.58---3.64------
Biostax Corp0.00-1.65m3.01m-----------0.0198-0.01980.00-0.04560.00-------193.36-75.14---------------8.97--------53.32------
Target Group Inc5.64m228.87k3.05m46.0038.08--2.870.54150.00010.00010.0088-0.01150.7648.60124.27115,104.103.10-37.99---78.7643.71--4.06-586.970.07360.01493.10----577.8392.84---58.54--
Finch Therapeutics Group Inc0.00-16.28m3.12m18.00--0.1636-----10.14-10.140.0011.860.00-------25.22---28.97--------------0.00---87.57--34.80------
Data as of May 16 2024. Currency figures normalised to Veritas Farms Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.